News

The compound, MLN1202, is designed to block CCR2 chemokine receptors and prevent the infiltration of immune cells into inflammatory sites. The CCR2 chemokine pathway is believed to play

The partnership will investigate Reverse Cholesterol Transport (RCT) enhancing compounds for the treatment of cardiovascular disease. These medicines are designed to directly increase the flow of lipids from

The grant is designed to help VistaGen progress its lead drug candidate AV-101 (4-Cl-KYN) through developmental trials. VistaGen will complete preclinical efficacy studies for AV-101 for use as

The so-called Breath-5 study evaluated the use of Tracleer (bosentan) in patients with Eisenmenger’s syndrome, a progressive heart condition that occurs in people who have a congenital heart

The technologies were developed at the Imperial College London, the base from which NovaThera was originally formed. Pharming and NovaThera are to collaborate on combining NovaThera’s proprietary biomaterial

NPS submitted the application on May 10, 2005, and the FDA has now made a threshold determination that the Preos NDA is sufficiently complete to permit a substantive

HCT 1026 is a nitric oxide-donating derivative of flurbiprofen, an anti-inflammatory drug useful in the treatment of arthritis. These results demonstrate the potential utility of nitric oxide-donation in

If approved for this indication, Femara will become the only breast cancer treatment available to significantly reduce the risk of recurrence in the post-surgery setting as well as

In controlled clinical trials, patients taking a Roche anti-amyloid drug candidate for Alzheimer’s disease will be monitored clinically for drug response using GE’s positron emission tomography (PET) diagnostic